Brinter Inc
Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.
Industries
Nr. of Employees
small (1-50)
Brinter Inc
Brinter Inc is currently seeking investment
Brinter Inc is seeking a series-a investment in the range of 1m-5m
Products
Modular multi-material 3D bioprinter (research and professional models)
A modular desktop/benchtop 3D bioprinting system that supports multiple interchangeable toolheads for printing hydrogels with cells, pastes, thermoplastics and granulates; configurable with accessories such as mini-PC, laminar hood and medical-grade compressor.
Modular multi-material 3D bioprinter (research and professional models)
A modular desktop/benchtop 3D bioprinting system that supports multiple interchangeable toolheads for printing hydrogels with cells, pastes, thermoplastics and granulates; configurable with accessories such as mini-PC, laminar hood and medical-grade compressor.
Expertise Areas
- 3D bioprinting platform development
- Tissue engineering and regenerative medicine
- Orthopedic implant design and development
- Patient-specific/precision bioprinting
Key Technologies
- Extrusion-based bioprinting
- Screw-extrusion granulate printing
- Triaxial/concentric extrusion toolheads
- Modular multi-material printheads
Key People
Investors
Pre Seed Round - BRINTER
$750,000 funded.
Announced on 2023-02-16.
Innovestor
$1,460,730 funded.
Announced on 2021-06-10.
Pre Seed Round - BRINTER
$750,000 funded.
Announced on 2023-02-16.
Innovestor
$1,460,730 funded.
Announced on 2021-06-10.
News & Updates
Brinter, a leader in 3D-bioprinted regenerative implants, has been recognized by TIME Magazine as one of the Best Inventions of 2025, highlighting the company’s breakthrough approach to next-generation medical devices.
Each year, TIME selects innovations that are reshaping their industries and pushing the boundaries of what’s possible. Brinter earned its place on the prestigious list for pioneering BioMods™—3D-bioprinted biocomposite implants designed to strengthen tissue repair, accelerate healing, and offer fully resorbable alternatives to traditional orthopedic and soft-tissue solutions.
The recognition reflects Brinter’s rapid advancement in both technology and clinical impact. With its patented Brinter CORE multi-material bioprinting platform and a pipeline of regenerative implants targeting orthopedics and aesthetics, the company is redefining how the world approaches human reconstructive care.
This milestone comes as Brinter continues its regulatory progress, including submitting its Q-Sub to the FDA—a key step on the path toward U.S. market clearance.
Brinter’s inclusion in TIME’s Best Inventions list underscores its position at the forefront of biofabrication and signals a major leap forward in the future of regenerative medicine.
Brinter, a leader in 3D-bioprinted regenerative implants, has been recognized by TIME Magazine as one of the Best Inventions of 2025, highlighting the company’s breakthrough approach to next-generation medical devices. Each year, TIME selects innovations that are reshaping their industries and pushing the boundaries of what’s possible. Brinter earned its place on the prestigious list for pioneering BioMods™—3D-bioprinted biocomposite implants designed to strengthen tissue repair, accelerate healing, and offer fully resorbable alternatives to traditional orthopedic and soft-tissue solutions. The recognition reflects Brinter’s rapid advancement in both technology and clinical impact. With its patented Brinter CORE multi-material bioprinting platform and a pipeline of regenerative implants targeting orthopedics and aesthetics, the company is redefining how the world approaches human reconstructive care. This milestone comes as Brinter continues its regulatory progress, including submitting its Q-Sub to the FDA—a key step on the path toward U.S. market clearance. Brinter’s inclusion in TIME’s Best Inventions list underscores its position at the forefront of biofabrication and signals a major leap forward in the future of regenerative medicine.